Business Context and Reporting Period
This Form 8-K reports the results of the 2026 Annual Meeting of Stockholders held by Cartesian Therapeutics, Inc. on June 12, 2026. The filing details the voting outcomes for director elections, executive compensation, and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
A total of 24,151,536 shares were present or represented by proxy, representing approximately 82.42% of outstanding common stock. The following proposals were voted upon:
- Proposal 1 (Election of Directors): All three Class I nominees were elected.
- Michael Singer, M.D., Ph.D.: 11,745,619 votes FOR; 8,083,506 votes WITHHELD.
- Timothy A. Springer, Ph.D.: 18,665,163 votes FOR; 1,163,962 votes WITHHELD.
- Patrick Zenner, M.B.A: 12,168,919 votes FOR; 7,660,206 votes WITHHELD.
- Proposal 2 (Executive Compensation): Approved on a non-binding advisory basis.
- Votes FOR: 13,659,709
- Votes AGAINST: 136,217
- Votes ABSTAINED: 6,033,199
- Proposal 3 (Auditor Ratification): Ratified the appointment of Ernst & Young LLP for the year ending December 31, 2026.
- Votes FOR: 24,144,742
- Votes AGAINST: 6,157
- Votes ABSTAINED: 637
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the high number of withheld votes for nominees Michael Singer and Patrick Zenner compared to Timothy A. Springer.
- Confirm the significant number of abstentions (6,033,199) regarding the executive compensation proposal.
- Review the full Proxy Statement referenced in the filing for detailed rationale behind the voting proposals.
- Check subsequent filings for the company's financial performance, as this 8-K contains no financial data.